Vanda Pharmaceuticals (VNDA) Tops Q2 EPS by 31c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Vanda Pharmaceuticals Reports Second Quarter 2017 Financial Results
August 2, 2017 4:01 PM EDTWASHINGTON, Aug. 2, 2017 /PRNewswire/ --Â Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ: VNDA) today announced financial and operational results for the second quarter ended June 30, 2017.
"During the second quarter of 2017, we advanced our company growth strategy and delivered strong operational and financial results," said Mihael H. Polymeropoulos, M.D., Vanda's President and CEO.
Key Highlights:
Total net product sales from HETLIOZ® and Fanapt® were $42.1 million during the second quarter of 2017, a 12% increase compared to $37.4 million in the first quarter of 2017 and a 17% increase compared to $36.0 million in the second... More